6-Bromo-1H-pyrrolo[3,2-b]pyridine-3-carboxylic acid, 95.0%, 100mg

Boc-L-6-Hydroxynorleucine, 95.0%, 250mg

Tablier aluminisé V5KA avec manches

3-(2,4-Dichlorophenoxymethyl)-4-methoxy-benzaldehyde, 100mg

3-((((9h-Fluoren-9-yl)methoxy)carbonyl)amino)-2-methylpropanoic acid, 95+%, 250mg

1,3-benzoxazol-2-yl 3-benzyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl sulfide, 98%, 50mg

BMPyrr TFSI, 100 g, >=99%, emballage en verre

Flacons à fond rond à double col et col latéral parallèle, 4000 ml, 29/32, 1 pièce

(R)-1-(2,4-Difluorophenyl)ethanamine, 95.0%, 100mg

1',5',6',7'-tetrahydrospiro[cyclohexane-1,2'-cyclopenta[d]pyrimidin]-4'(3'H)-one, 95.0%, 250mg

Ethyl 8-(4-t-butylphenyl)-8-oxooctanoate, 97.0%, 1g

2,2-Difluorocyclopropylamine hydrochloride, 97.0%, 5g

2,2-Difluoro-5-nitrobenzo[d][1,3]dioxole, 97.0%, 10g